Suppr超能文献

乳腺腺样囊性癌的管理:一项单机构研究

Management of Adenoid Cystic Carcinoma of the Breast: A Single-Institution Study.

作者信息

Zhang Wenxiang, Fang Yi, Zhang Zhihui, Wang Jing

机构信息

Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Cytology Section Department of Pathology, National Cancer Centre/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Front Oncol. 2021 Mar 15;11:621012. doi: 10.3389/fonc.2021.621012. eCollection 2021.

Abstract

OBJECTIVE

The purpose of our study was to analyze the clinicopathologic features and surgical and oncological outcomes of adenoid cystic carcinoma (ACC) of the breast and to provide the basis for a clinical therapeutic schedule.

METHODS

A total of 14 patients with primary breast adenoid cystic carcinoma treated at Cancer Hospital of the Chinese Academy of Medical Sciences from January 2000 to December 2017 were included. Data on clinical presentation, treatment strategy, and outcome, as well as the pathological features of ACC, were reviewed and analyzed.

RESULTS

Fourteen patients were diagnosed with ACC of the breast, out of 23205 total patients treated for breast cancer (0.06%). All but three patients were postmenopausal, with a median age at diagnosis of 60.5 years (range, 39-73 years). The most common clinical presentation was a palpable mass (85.7%), and the imaging characteristics of all patients on color Doppler ultrasound and mammography were nonspecific. Six patients (42.9%) were suspected of having ACC by fine-needle aspiration cytology (FNAC) and were confirmed by postoperative histology and immunohistochemistry. All 14 patients underwent surgery, and no patient had a positive lymph node status. Median tumor size was 1.75 cm (range, 1-3 cm). Eight/14 (57.1%) patients were hormone receptor negative (HR-) and HER-2/neu (-) (HER2-). The remaining patients were hormone receptor positive (HR+). There was no significant difference in clinicopathological characteristics between the HR+ group and the HR- group (P>0.05). The mean follow-up period was 57 months. Local recurrence occurred in 14.3% of patients, 1.7% of patients had distant metastasis, all patients with local recurrence or distant metastasis were in the HR (-) group, and all patients were alive at the last follow-up.

CONCLUSION

ACC of the breast cannot be simply summarized as triple-negative breast cancer because it also includes a small number of hormone receptor-positive breast cancers. Establishing a preoperative diagnosis is difficult on the basis of clinical imaging examination, FNAC may be useful tool in the diagnosis. the final diagnosis can only be assessed based on the results of the histopathological and immunohistochemical examination. Breast-conserving surgery may be an alternative treatment strategy, and axillary lymph node dissection or sentinel node biopsy may not be necessary in some cases.

摘要

目的

本研究旨在分析乳腺腺样囊性癌(ACC)的临床病理特征、手术及肿瘤学结局,为临床治疗方案提供依据。

方法

纳入2000年1月至2017年12月在中国医学科学院肿瘤医院接受治疗的14例原发性乳腺腺样囊性癌患者。回顾并分析临床表现、治疗策略、结局以及ACC的病理特征等数据。

结果

在23205例接受乳腺癌治疗的患者中,14例被诊断为乳腺ACC(0.06%)。除3例患者外均为绝经后女性,诊断时的中位年龄为60.5岁(范围39 - 73岁)。最常见的临床表现是可触及肿块(85.7%),所有患者彩色多普勒超声和乳腺钼靶的影像学特征均不具有特异性。6例患者(42.9%)经细针穿刺细胞学检查(FNAC)怀疑为ACC,并经术后组织学和免疫组化确诊。14例患者均接受了手术,无患者出现淋巴结阳性。肿瘤中位大小为1.75 cm(范围1 - 3 cm)。14例中有8例(57.1%)患者激素受体阴性(HR -)且HER - 2/neu(-)(HER2 -)。其余患者激素受体阳性(HR +)。HR +组和HR -组的临床病理特征无显著差异(P>0.05)。平均随访期为57个月。14.3%的患者发生局部复发,1.7%的患者发生远处转移,所有局部复发或远处转移的患者均在HR(-)组,最后一次随访时所有患者均存活。

结论

乳腺ACC不能简单地归纳为三阴性乳腺癌,因为它还包括少数激素受体阳性乳腺癌。基于临床影像学检查难以进行术前诊断,FNAC可能是诊断的有用工具。最终诊断只能根据组织病理学和免疫组化检查结果来评估。保乳手术可能是一种替代治疗策略,在某些情况下可能无需进行腋窝淋巴结清扫或前哨淋巴结活检。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4211/8005703/b903acf06cca/fonc-11-621012-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验